

## AUSTEDO XR - (6MG, 12MG, 24MG, 30MG, 36MG, 42MG, 48MG, 18MG ; TABLET,EXTENDED RELEASE)

<b>Generic Name</b>	DEUTETRABENAZINE	<b>Innovator</b>	Teva
<b>Dosage</b>	6MG, 12MG, 24MG, 30MG, 36MG, 42MG, 48MG, 18MG ; TABLET,EXTENDED RELEASE	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	AUSTEDO XR is vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of: • Chorea associated with Huntington's disease • Tardive dyskinesia		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.